← All trials
NCT02787044
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2016
- Primary completion
- Aug 1, 2020
- Completion date
- Feb 1, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 9300
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Harvard UniversityLead sponsor
- University of WisconsinOverall official - principal investigator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- University of TorontoCollaborator
- University of WisconsinCollaborator
- Harvard UniversityOverall official - principal investigator
- Harvard UniversityReponsible party - principal investigator
- Cancer Research NetworkCollaborator
- Department of Veteran AffairsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.